Breaking News Instant updates and real-time market news.

MYL

Mylan

$29.98

-0.37 (-1.22%)

10:10
02/08/19
02/08
10:10
02/08/19
10:10

Second day of interest in Mylan Mar 32.5 calls

Second day of interest in Mylan Mar 32.5 calls. 4.2K changed hands yesterday and, with shares off 30c to $30.05 Friday morning, buyers pay 61 and 62c per contract: 1.7K traded against 1.5K open interest.

MYL Mylan
$29.98

-0.37 (-1.22%)

01/31/19
WELS
01/31/19
NO CHANGE
WELS
Outperform
FDA approval of Mylan's Advair 'overdue,' says Wells Fargo
Wells Fargo analyst David Maris believes that while "overdue," FDA's approval of Mylan's (MYL) generic Advair is good news. Many investors were expecting this to be further delayed, he notes, adding that he currently has $50M generic Advair in his model for Q1. The analyst believes GlaxoSmithKline (GSK) will launch an authorized generic, and with Advair's already declining revenue, the generic Advair opportunity may turn out to be a great-to-have since it shows Mylan's ability to get complex generics approved, but may not be a game changer. Maris reiterates an Outperform rating on Mylan's shares.
02/06/19
PIPR
02/06/19
NO CHANGE
Target $402
PIPR
Overweight
Successful challenge of Biogen's '514 patent unlikely, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $402 price target on Biogen (BIIB) after the latest filing disclosing that Mylan (MYL) petitioned U.S. PTAB to review its '514 patent covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in Biogen's Tecfidera label. The analyst notes that while the worst case scenario could remove about $50 per share from his sum-of-parts analysis on Biogen, he sees it as "unlikely", since the patent has been resilient to two prior challenges which were decided in Biogen's favor.
02/07/19
MZHO
02/07/19
NO CHANGE
Target $427
MZHO
Buy
Mizuho likes Biogen's odds in patent case against Mylan
Shares of Biogen (BIIB) are trading down about 3% after Mylan's (MYL) inter partes review on key multiple sclerosis drug Tecfidera got "instituted," Mizuho analyst Salim Syed tells investors in a research note. The timing was as expected, and most biotech IPRs in general get instituted, explains the analyst. He says that while historical biotech IPR data suggests Biogen has a 31% chance of losing, the company's odds are "materially less" for two reasons. One, Tecfidera intellectual property is already "battle-tested," and two, there are 20 claims being disputed in this IPR and Mylan needs to win on all of them while Biogen needs to win on only one claim to be successful, Syed writes. He has a Buy rating on Biogen with a $427 price target.
02/07/19
CANT
02/07/19
NO CHANGE
Target $33
CANT
Neutral
Mylan patent challenge on Tecfidera potential positive for Alkermes, says Cantor
Cantor Fitzgerald analyst Brandon Folkes views the institution of Mylan's (MYL) inter partes review challenge of Tecfidera's '514 patent as a potential positive for Alkermes (ALKS). The analyst has assumed Biogen's (BIIB) Tecfidera '514 patent holds through 2028, and thus had ascribed a "more-modest" value to Alkermes' royalty from BIIB098 sales. If Mylan is successful in its IPR challenge, says the analyst, it could provide $4-$7 per share upside to his current Alkermes price target of $33. Biogen reported Tecfidera revenues of $4.3B for 2018, $3.3B of which was generated in the U.S. Alkermes is entitled to a mid-teen royalty on worldwide sales of BIIB098, Folkes tells investors in a research note titled "Giving ALKS a Hall Pass to Support the Away Team This Time." However, he believes the market has discounted the contribution of the BIIB098 royalty to Alkermes, "given the uncertainty about how the product may be included in a Tecfidera life cycle extension given the '514 patent runs to 2028."

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Upgrade
Seattle Genetics rating change  »

Seattle Genetics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Week of 7/12 MBA Mortgage…

KSHB

KushCo Holdings

$0.00

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
KushCo Holdings management to meet with Compass Point »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TELL

Tellurian

$7.68

-0.1 (-1.29%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Tellurian management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CRD.B

Crawford & Company

$9.34

-0.13 (-1.37%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Crawford & Company management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DOVA

Dova Pharmaceuticals

$16.07

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Dova Pharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Analysts provide a 2Q…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

, FTNT

Fortinet

$84.79

-0.19 (-0.22%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Analyst Seyrafi holds a…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

FTNT

Fortinet

$84.79

-0.19 (-0.22%)

PFPT

Proofpoint

$126.33

0.61 (0.49%)

CHKP

Check Point

$116.24

-1.37 (-1.16%)

SAIL

SailPoint

$20.12

-0.27 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 01

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 13

    Nov

OVID

Ovid Therapeutics

$2.39

-0.19 (-7.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Ovid Therapeutics management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CLNE

Clean Energy

$2.75

-0.01 (-0.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Clean Energy management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 08

    Aug

VFF

Village Farms

$9.29

-0.125 (-1.33%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Village Farms management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CASY

Casey's General Stores

$160.35

0.98 (0.61%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 13

    Nov

CTSO

CytoSorbents

$7.19

0.14 (1.99%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
CytoSorbents management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Credit Suisse financial analysts to hold an analyst/industry conference call »

Analysts provide a market…

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Beige Book to be released…

CDTX

Cidara Therapeutics

$1.60

-0.01 (-0.62%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Cidara Therapeutics management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GMRE

Global Medical REIT

$10.66

-0.01 (-0.09%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Global Medical REIT management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 08

    Aug

ULTA

Ulta Beauty

$360.68

4.97 (1.40%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Ulta Beauty management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 29

    Aug

  • 25

    Sep

EPD

Enterprise Products

$30.32

0.005 (0.02%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
UBS energy analyst to hold an analyst/industry conference call »

Energy Analyst Gershuni…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 31

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Housing Starts Permits to be reported at 08:30 »

June Housing Starts…

CPXGF

Cineplex

$0.00

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Cineplex management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Kansas City Federal…

SNPS

Synopsys

$135.93

-1.53 (-1.11%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Synopsys management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

TEUM

Pareteum

$3.22

0.01 (0.31%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Pareteum management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 23

    Jul

  • 24

    Jul

  • 06

    Aug

  • 12

    Sep

LZB

La-Z-Boy

$32.37

0.385 (1.20%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
La-Z-Boy management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.